Your browser doesn't support javascript.
Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs.
Smetanova, Jitka; Milota, Tomas; Rataj, Michal; Hurnakova, Jana; Zelena, Hana; Sediva, Anna; Horvath, Rudolf.
  • Smetanova J; Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia.
  • Milota T; Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia.
  • Rataj M; Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia.
  • Hurnakova J; Department of Paediatric and Adult Rheumatology, Motol University Hospital, Prague, Czechia.
  • Zelena H; Department of Virology, Public Health Institute, Ostrava, Czechia.
  • Sediva A; Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia.
  • Horvath R; Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia.
Front Immunol ; 13: 1010808, 2022.
Article in English | MEDLINE | ID: covidwho-2065525
ABSTRACT

Background:

Vaccination confers relatively short-term protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), indicating the need for booster doses. Immunocompromised individuals, including those with immune-mediated inflammatory diseases (IMIDs), may have pronounced immune response waning. Vaccine-boosted humoral and T-cell responses minimize poor coronavirus disease 19 (COVID-19) outcome without increasing adverse events (AE). There is limited evidence of third-dose vaccination in axial spondyloarthritis (AxSpA) patients. We investigated immune-response persistence after primary vaccination and immunogenicity and safety after the BNT162b2 booster vaccination.

Methods:

This prospective observational study enrolled an AxSpA cohort treated with interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNFα) inhibitors. Serum SARS-CoV-2-specific and virus-neutralizing antibodies for humoral response and flow cytometric detection of intracellular cytokines following SARS-CoV-2-specific peptide-based stimulation for T-cell immune responses were assessed, and safety was evaluated via a clinical questionnaire.

Results:

Fifteen male AxSpA patients treated with TNFα (73·3%) or IL-17 (26·7%) inhibitors were enrolled and had humoral response persistence at 6 months 905·6 ( ± 186·1 SD) and 409·1 ( ± 335·7) U/mL. Specific antibody concentrations further increased after booster vaccination to 989·7 ( ± 12·62) and 1000 U/mL and T-cell responders from 53·3% to 80%, with no differences between AxSpA (including "vaccination only" and "hybrid immunity" subgroups) and healthy control (HC) cohorts. No severe AE occurred; the AE spectrum was comparable to that of the general population.

Conclusion:

Immune-response persistence after primary vaccination and immunogenicity after booster vaccination were unaffected by anti-IL17 or anti-TNFα therapy with similar AE as in the general population.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / COVID-19 / Axial Spondyloarthritis Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans / Male Language: English Journal: Front Immunol Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / COVID-19 / Axial Spondyloarthritis Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans / Male Language: English Journal: Front Immunol Year: 2022 Document Type: Article